The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw ...

Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw ...

The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional ...

Anlotinib plus chemotherapy demonstrated similar efficacy as bevacizumab plus chemotherapy for certain patients with ...

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses a phase 3 clinical trial investigating amivantamab in metastatic colorectal cancer.

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

New phase 1 findings highlight promise of first-in-class bispecific antibody fusion for advanced colorectal cancer.

A team of researchers at the University of Minnesota recently completed a human trial for a novel gene-editing treatment, ...